2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Not approvedWill not start
The primary outcome is the occurrence of neonatal respiratory morbidity within 24 hours after birth. Painful contractions. Progression of labour after stopping OCT. Nonreassuring fetal heart rate pattern during OCT.